Susanne Berchtold

Title: Susanne Berchtold: Innovator in Oncolytic Virus Research

Introduction

Susanne Berchtold is a prominent inventor based in Tuebingen, Germany. She has made significant contributions to the field of pharmaceutical compositions, particularly in the development of oncolytic viruses for cancer treatment. With a total of 2 patents, her work is paving the way for innovative therapies in oncology.

Latest Patents

One of her latest patents focuses on an oncolytic measles virus. This invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene. It is designed for use in the treatment of malignant cells that exhibit primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Additionally, the invention includes a recombinant measles virus based on the measles vaccine strain Schwarz, which encodes a suicide gene. This gene comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase. The patent also details a method and a kit for preparing the recombinant measles virus as claimed.

Career Highlights

Throughout her career, Susanne has focused on innovative solutions in the medical field. Her research has been instrumental in advancing the understanding and application of oncolytic viruses in cancer therapy.

Collaborations

Susanne has collaborated with notable professionals in her field, including Ulrich Manfred Lauer and Michael Bitzer. These collaborations have further enhanced her research and contributions to the scientific community.

Conclusion

Susanne Berchtold's work in the development of oncolytic viruses represents a significant advancement in cancer treatment. Her innovative approach and dedication to research continue to inspire progress in the field of oncology.